Balchem Is Maintained at Buy by HC Wainwright & Co.
H.C. Wainwright Maintains Balchem(BCPC.US) With Buy Rating, Raises Target Price to $190
Balchem's Strong Growth Potential and Strategic Advancements Drive Buy Rating
Balchem Analyst Ratings
Buy Rating Affirmed for Balchem With Raised Price Target Amidst Strong Profitability and Growth Prospects
H.C. Wainwright Maintains Balchem(BCPC.US) With Buy Rating, Raises Target Price to $185
Balchem Analyst Ratings
Buy Rating Affirmed for Balchem With Strong Q1 Performance and Positive Growth Outlook
HC Wainwright & Co. Maintains Buy on Balchem, Lowers Price Target to $135
Balchem Analyst Ratings
HC Wainwright & Co. Maintains Buy on Balchem, Raises Price Target to $165
Balchem Analyst Ratings
HC Wainwright Adjusts Price Target on Balchem to $150 From $140, Keeps Buy Rating
Analysts Offer Insights on Healthcare Companies: Agenus (AGEN) and Balchem (BCPC)
HC Wainwright & Co. Maintains Buy on Balchem, Raises Price Target to $150
HC Wainwright Adjusts Price Target on Balchem to $140 From $152, Keeps Buy Rating
HC Wainwright & Co. Maintains Buy on Balchem, Lowers Price Target to $140
HC Wainwright Adjusts Price Target on Balchem to $152 From $164, Maintains Buy Rating
Balchem Analyst Ratings
HC Wainwright & Co. Maintains Buy on Balchem, Lowers Price Target to $152